Fremont, CA — January 6, 2024
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in cell analysis solutions, will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
About Cytek Biosciences, Inc.:
Cytek Biosciences (Nasdaq: CTKB) is at the forefront of cell analysis solutions, delivering high-resolution, high-content and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP™) technology. The company plays a key role in driving the development of next-generation cell analysis tools. Cytek’s innovative methods harness the power of information across the entire fluorescence spectrum to enable precise, sensitive and advanced multiplex analysis. Cytek’s comprehensive FSP platform includes the Cytek Aurora™ and Northern Lights™ systems, the Cytek Aurora™ CS cell sorter, and flow cytometry and imaging products under the Amnis® and Guava® brands. The company also provides reagents, software and services to provide customers with comprehensive solutions.
Headquartered in Fremont, California, Cytek operates globally through its offices and distribution channels.
Important tips:
Cytek’s products are for research use only and are not authorized for use in diagnostic procedures, except for certain products available for clinical use in China and the European Union.
Investors and stakeholders are encouraged to monitor Cytek’s website, LinkedIn page and other financial communication channels for updates, announcements and disclosures.
As Cytek Biosciences takes the stage at the J.P. Morgan Healthcare Conference, it will continue to drive innovation and contribute to the advancement of cell analysis technology.
